Maura L. Gillison
#124,041
Most Influential Person Now
Maura L. Gillison's AcademicInfluence.com Rankings
Maura L. Gillisonmedical Degrees
Medical
#1944
World Rank
#2332
Historical Rank
Oncology
#103
World Rank
#107
Historical Rank
Epidemiology
#319
World Rank
#336
Historical Rank
Maura L. Gillisonphilosophy Degrees
Philosophy
#5738
World Rank
#8628
Historical Rank
Logic
#2960
World Rank
#4045
Historical Rank
Download Badge
Medical Philosophy
Why Is Maura L. Gillison Influential?
(Suggest an Edit or Addition)Maura L. Gillison's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Human papillomavirus and survival of patients with oropharyngeal cancer. (2010) (4482)
- Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. (2000) (2990)
- Human papillomavirus and rising oropharyngeal cancer incidence in the United States. (2011) (2980)
- Case-control study of human papillomavirus and oropharyngeal cancer. (2007) (2569)
- Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. (2008) (2527)
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. (2016) (1900)
- Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. (2008) (1499)
- Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. (2008) (1474)
- Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. (2013) (1071)
- Prevalence of oral HPV infection in the United States, 2009-2010. (2012) (955)
- Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. (2015) (759)
- Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial (2019) (716)
- Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. (2014) (627)
- Oral sexual behaviors associated with prevalent oral human papillomavirus infection. (2009) (582)
- Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. (2004) (568)
- Clinical implications of human papillomavirus in head and neck cancers. (2006) (516)
- HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women (2008) (482)
- Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. (2018) (477)
- Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. (2020) (454)
- Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. (2012) (431)
- Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. (2014) (400)
- Human Papillomavirus in Head and Neck Cancer: Its Role in Pathogenesis and Clinical Implications (2009) (394)
- Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. (2004) (393)
- NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018. (2018) (381)
- Genome-wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability (2014) (345)
- Validation of Methods for Oropharyngeal Cancer HPV Status Determination in US Cooperative Group Trials (2012) (343)
- Tissue Distribution of Human Papillomavirus 16 DNA Integration in Patients with Tonsillar Carcinoma (2005) (336)
- E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. (2017) (335)
- Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. (2014) (332)
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) (2019) (327)
- Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. (2009) (320)
- Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas. (2013) (320)
- Burden of potentially human papillomavirus‐associated cancers of the oropharynx and oral cavity in the US, 1998–2003 (2008) (312)
- Human papillomavirus–associated head and neck squamous cell carcinoma: mounting evidence for an etiologic role for human papillomavirus in a subset of head and neck cancers (2001) (309)
- p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma. (2014) (300)
- Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. (2003) (296)
- NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017. (2017) (285)
- Current topics in the epidemiology of oral cavity and oropharyngeal cancers (2007) (285)
- Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. (2017) (276)
- Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. (2012) (259)
- Elevated incidence of lung cancer among HIV-infected individuals. (2006) (258)
- Comprehensive control of human papillomavirus infections and related diseases. (2013) (247)
- Human papillomavirus-related oropharyngeal cancer (2017) (244)
- Detection of Human Papillomavirus-16 in Fine-Needle Aspirates to Determine Tumor Origin in Patients with Metastatic Squamous Cell Carcinoma of the Head and Neck (2007) (231)
- EUROGIN 2011 roadmap on prevention and treatment of HPV‐related disease (2012) (231)
- Chapter 9: Role of mucosal human papillomavirus in nongenital cancers. (2003) (227)
- Head and neck squamous cell cancer and the human papillomavirus: Summary of a National Cancer Institute State of the Science Meeting, November 9–10, 2008, Washington, D.C. (2009) (223)
- HEAD AND NECK SQUAMOUS CELL CANCER AND THE HUMAN PAPILLOMAVIRUS: SUMMARY OF A NATIONAL CANCER INSTITUTE STATE OF THE SCIENCE MEETING, (2009) (220)
- Risk Factors for Oral HPV Infection among a High Prevalence Population of HIV-Positive and At-Risk HIV-Negative Adults (2011) (210)
- Institutional clinical trial accrual volume and survival of patients with head and neck cancer. (2015) (206)
- Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. (2003) (191)
- A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). (2011) (190)
- Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma. (2000) (190)
- Eurogin Roadmap: Comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix (2014) (187)
- Head and Neck Cancers, Version 1.2015. (2015) (186)
- Head and neck cancers: Clinical practice guidelines in oncology (2011) (178)
- Effect of Prophylactic Human Papillomavirus (HPV) Vaccination on Oral HPV Infections Among Young Adults in the United States. (2017) (177)
- The Prevalence and Incidence of Oral Human Papillomavirus Infection Among Young Men and Women, Aged 18–30 Years (2012) (171)
- Six‐month natural history of oral versus cervical human papillomavirus infection (2007) (171)
- NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022. (2022) (165)
- Human papillomavirus in HNSCC: recognition of a distinct disease type. (2008) (163)
- Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. (2014) (160)
- Discrimination between related DNA sites by a single amino acid residue of Myc-related basic-helix-loop-helix proteins. (1992) (156)
- Human papillomavirus-related diseases: oropharynx cancers and potential implications for adolescent HPV vaccination. (2008) (152)
- Associations between Oral HPV16 Infection and Cytopathology: Evaluation of an Oropharyngeal “Pap-Test Equivalent” in High-Risk Populations (2011) (149)
- Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners. (2014) (148)
- Real-time quantitative PCR demonstrates low prevalence of human papillomavirus type 16 in premalignant and malignant lesions of the oral cavity. (2002) (147)
- Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. (2013) (147)
- Head and Neck Cancers, Version 2.2014 (2014) (145)
- Human papillomavirus in head and neck squamous cell carcinoma: are some head and neck cancers a sexually transmitted disease? (1999) (141)
- Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399. (2007) (136)
- Comprehensive control of human papillomavirus infections and related diseases. (2013) (134)
- Delayed Diagnosis and Elevated Mortality in an Urban Population With HIV and Lung Cancer: Implications for Patient Care (2006) (133)
- Head and Neck Cancers, Version 2.2013 (2013) (132)
- Human papillomavirus and the landscape of secondary genetic alterations in oral cancers (2018) (129)
- Relationship between Prevalent Oral and Cervical Human Papillomavirus Infections in Human Immunodeficiency Virus-Positive and -Negative Women (2006) (127)
- Estimating and explaining the effect of education and income on head and neck cancer risk: INHANCE consortium pooled analysis of 31 case‐control studies from 27 countries (2015) (127)
- Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adults. (2015) (125)
- Moderate predictive value of demographic and behavioral characteristics for a diagnosis of HPV16-positive and HPV16-negative head and neck cancer. (2010) (122)
- Human papillomavirus and prognosis of oropharyngeal squamous cell carcinoma: implications for clinical research in head and neck cancers. (2006) (118)
- Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. (2014) (114)
- Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer. (2017) (108)
- NHANES 2009-2012 Findings: Association of Sexual Behaviors with Higher Prevalence of Oral Oncogenic Human Papillomavirus Infections in U.S. Men. (2015) (108)
- Chapter 16: HPV vaccines in immunocompromised women and men. (2006) (106)
- Survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129. (2009) (105)
- Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002) (2021) (103)
- Analysis of the Effect of DNA Purification on Detection of Human Papillomavirus in Oral Rinse Samples by PCR (2005) (100)
- Natural history of anal vs oral HPV infection in HIV-infected men and women. (2013) (99)
- Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. (2018) (98)
- Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use (2019) (95)
- Evolution of the Oropharynx Cancer Epidemic in the United States: Moderation of Increasing Incidence in Younger Individuals and Shift in the Burden to Older Individuals. (2019) (94)
- Assessment of Human Papillomavirus in Lung Tumor Tissue (2011) (91)
- Alterations in oral bacterial communities are associated with risk factors for oral and oropharyngeal cancer (2017) (88)
- Karyoplasmic interaction selection strategy: a general strategy to detect protein-protein interactions in mammalian cells. (1992) (88)
- Prognostic Implication of Persistent Human Papillomavirus Type 16 DNA Detection in Oral Rinses for Human Papillomavirus-Related Oropharyngeal Carcinoma. (2015) (83)
- No role for human papillomavirus in esophageal squamous cell carcinoma in China (2010) (80)
- Oropharyngeal cancer: a potential consequence of concomitant HPV and HIV infection (2009) (79)
- Gender Differences in Sexual Biomarkers and Behaviors Associated With Human Papillomavirus-16, −18, and −33 Seroprevalence (2004) (79)
- Comprehensive control of human papillomavirus infections and related diseases. (2013) (77)
- A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141. (2017) (76)
- Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma. (2003) (76)
- Smokeless Tobacco Use and the Risk of Head and Neck Cancer: Pooled Analysis of US Studies in the INHANCE Consortium. (2016) (76)
- Burden of HPV-positive oropharynx cancers among ever and never smokers in the U.S. population. (2016) (76)
- NRG-HN002: A Randomized Phase II Trial for Patients With p16-Positive, Non-Smoking-Associated, Locoregionally Advanced Oropharyngeal Cancer (2019) (75)
- Oral Human Papillomavirus Infection Before and After Treatment for Human Papillomavirus 16–Positive and Human Papillomavirus 16–Negative Head and Neck Squamous Cell Carcinoma (2008) (73)
- Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311) (2021) (72)
- Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311). (2020) (69)
- Tobacco use and oral HPV-16 infection. (2014) (67)
- CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. (2018) (63)
- Sex Differences in Risk Factors and Natural History of Oral Human Papillomavirus Infection. (2016) (62)
- Prevalence of cervical and oral human papillomavirus infections among US women. (2014) (59)
- Variations in HPV function are associated with survival in squamous cell carcinoma. (2019) (59)
- E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC). (2014) (58)
- Association of Oral Human Papillomavirus DNA Persistence With Cancer Progression After Primary Treatment for Oral Cavity and Oropharyngeal Squamous Cell Carcinoma. (2019) (58)
- HPV integration hijacks and multimerizes a cellular enhancer to generate a viral-cellular super-enhancer that drives high viral oncogene expression (2018) (57)
- Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial (2019) (56)
- HPV and prognosis for patients with oropharynx cancer. (2009) (56)
- HEAD AND NECK SQUAMOUS CELL CANCER AND THE HUMAN PAPILLOMAVIRUS : SUMMARY OF A NATIONAL CANCER INSTITUTE STATE OF THE SCIENCE MEETING , NOVEMBER (2009) (55)
- The Fanconi Anemia Pathway Limits Human Papillomavirus Replication (2012) (54)
- A new link between Fanconi anemia and human papillomavirus-associated malignancies. (2003) (53)
- Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141. (2016) (52)
- De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies (2020) (48)
- Phase II multi-site investigation of neoadjuvant pembrolizumab and adjuvant concurrent radiation and pembrolizumab with or without cisplatin in resected head and neck squamous cell carcinoma. (2018) (48)
- Two-Week versus Six-Month Sampling Interval in a Short-Term Natural History Study of Oral HPV Infection in an HIV-Positive Cohort (2010) (46)
- The use of ultrasound in the search for the primary site of unknown primary head and neck squamous cell cancers. (2014) (46)
- Prevalence of Oral HPV Infection in Unvaccinated Men and Women in the United States, 2009-2016. (2019) (46)
- Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results (2020) (46)
- Validation of NRG oncology/RTOG‐0129 risk groups for HPV‐positive and HPV‐negative oropharyngeal squamous cell cancer: Implications for risk‐based therapeutic intensity trials (2019) (45)
- Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting (2017) (45)
- DEK promotes HPV positive and negative head and neck cancer cell proliferation (2014) (44)
- Detection of HPV DNA in paraffin-embedded cervical samples: a comparison of four genotyping methods (2015) (42)
- Significant changes in sexual behavior after a diagnosis of human papillomavirus‐positive and human papillomavirus‐negative oral cancer (2017) (42)
- Abstract CT099: Nivolumab (nivo) vs investigator's choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141 (2016) (41)
- Automated high throughput DNA isolation for detection of human papillomavirus in oral rinse samples. (2011) (40)
- Head and neck surgical oncology in the time of a pandemic: Subsite‐specific triage guidelines during the COVID‐19 pandemic (2020) (38)
- Alcohol drinking and head and neck cancer risk: the joint effect of intensity and duration (2020) (38)
- HPV positive neuroendocrine cervical cancer cells are dependent on Myc but not E6/E7 viral oncogenes (2017) (35)
- High-risk oral human papillomavirus load in the US population, National Health and Nutrition Examination Survey 2009-2010. (2014) (34)
- HPV and its effect on head and neck cancer prognosis. (2010) (34)
- Mouthwash use and cancer of the head and neck: a pooled analysis from the International Head and Neck Cancer Epidemiology Consortium (2016) (33)
- Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study. (2015) (33)
- Nivolumab versus investigator’s choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age (2019) (32)
- 1043OTreatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: A biomarker analysis and updated clinical outcomes (2017) (32)
- Transcervical Ultrasonography Is Feasible to Visualize and Evaluate Base of Tongue Cancers (2014) (31)
- Human retinoblastoma is not caused by known pRb‐inactivating human DNA tumor viruses (2007) (30)
- Oral Human Papillomavirus (HPV) Infection among Unvaccinated High-Risk Young Adults (2014) (29)
- Safety evaluation of nivolumab (Nivo) concomitant with cetuximab-radiotherapy for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG 3504. (2018) (29)
- A phase 3, randomized, open-label study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL. (2016) (29)
- E 1308: A phase II trial of induction chemotherapy (IC) followed by cetuximab with low dose versus standard dose IMRT in patients with human papilloma virus (HPV)-associated resectable squamous cell carcinoma of the oropharynx (OPSCC). (2013) (28)
- Larynx preservation in head and neck cancers. A discussion of the National Comprehensive Cancer Network Practice Guidelines. (1999) (27)
- Low etiologic fraction for human papillomavirus in larynx squamous cell carcinoma. (2016) (27)
- Joint effects of intensity and duration of cigarette smoking on the risk of head and neck cancer: A bivariate spline model approach. (2019) (26)
- HPV knowledge gaps and information seeking by oral cancer patients. (2016) (26)
- Nivolumab (Nivo) vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety in CheckMate 141 by prior cetuximab use. (2017) (26)
- An empirical antigen selection method identifies neoantigens that either elicit broad anti-tumor T cell responses or drive tumor growth. (2021) (26)
- Phase II trial of trastuzumab (T), paclitaxel (P) and cisplatin (C) in metastatic (M) or recurrent (R) head and neck squamous cell carcinoma (HNSCC): Response by tumor EGFR and HER2/neu status. (2006) (26)
- Second Branchial Cleft Cyst: NOT!! (2009) (25)
- ECOG 1308: A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP). (2012) (25)
- Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI. (2020) (25)
- A Longitudinal Study of Human Papillomavirus 16 L1, E6, and E7 Seropositivity and Oral Human Papillomavirus 16 Infection (2015) (23)
- Racial differences in the relationship between tobacco, alcohol, and the risk of head and neck cancer: pooled analysis of US studies in the INHANCE Consortium (2018) (23)
- Defects in the Fanconi Anemia Pathway in Head and Neck Cancer Cells Stimulate Tumor Cell Invasion through DNA-PK and Rac1 Signaling (2015) (23)
- Human papillomavirus (HPV) and rising oropharyngeal cancer incidence and survival in the United States. (2011) (22)
- Oropharyngeal cancer survivorship in Denmark, 1977-2012. (2015) (22)
- HPV vaccines in immunocompromised women and men (2006) (22)
- A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first-line therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck-CheckMate 651 (2016) (22)
- Anticipation of the Impact of Human Papillomavirus on Clinical Decision Making for the Head and Neck Cancer Patient. (2015) (22)
- Nivolumab (Nivo) vs investigator’s choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): Outcomes in first-line (1L) R/m patients and updated safety and efficacy. (2017) (20)
- Abstract CT022: Evaluation of oral microbiome profiling as a response biomarker in squamous cell carcinoma of the head and neck: Analyses from CheckMate 141 (2017) (19)
- Mucosal melanoma of the head and neck. (2012) (19)
- Clonal cytogenetic abnormalities and BCL2 rearrangementin interdigitating dendritic cell sarcoma (2006) (19)
- Two‐year follow‐up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141) (2020) (19)
- Head and neck cancers. (2011) (18)
- Long-term Persistence of Oral HPV Over 7 Years of Follow-up (2020) (18)
- Abstract CT021: Tumor-associated immune cell PD-L1 expression and peripheral immune profiling: Analyses from CheckMate 141 (2017) (17)
- Dynamic factors affecting HPV-attributable fraction for head and neck cancers. (2019) (17)
- Association of pathological response to neoadjuvant pembrolizumab with tumor PD-L1 expression and high disease-free survival (DFS) in patients with resectable, local-regionally advanced, head and neck squamous cell carcinoma (HNSCC). (2021) (17)
- Human Papillomavirus-16 Associated Adenocarcinoma NOS of Base of Tongue (2013) (17)
- A Phase I Trial of Erlotinib and Concurrent Chemoradiotherapy for Stage III and IV (M0) Squamous Cell Carcinoma of the Head and Neck (2012) (17)
- LBA36 Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651 (2021) (17)
- Dose De-escalation in Human Papillomavirus-Associated Oropharyngeal Cancer: First Tracks on Powder. (2015) (17)
- Safety and disease control achieved with the addition of nivolumab (Nivo) to chemoradiotherapy (CRT) for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG Foundation 3504. (2019) (16)
- Prognostic impact of leukocyte counts before and during radiotherapy for oropharyngeal cancer (2017) (16)
- Evolving Role of Immunotherapy in Recurrent Metastatic Head and Neck Cancer. (2020) (16)
- Behavioral, Immunologic, and Virologic Correlates of Oral Human Papillomavirus Infection in HIV-Infected Youth (2015) (16)
- p16 expression as a human papillomavirus (HPV)-independent prognostic biomarker in non-oropharyngeal squamous cell carcinoma (non-OPSCC). (2013) (16)
- High Oral Human Papillomavirus Type 16 Load Predicts Long-term Persistence in Individuals With or at Risk for HIV Infection. (2015) (15)
- Reply to B. O'Sullivan et Al. (2015) (14)
- Checkpoint inhibitors assessment in oropharynx cancer (CIAO): Safety and interim results. (2019) (14)
- Nivolumab for Squamous-Cell Cancer of Head and Neck. (2017) (13)
- Analysis of the effect of p16 and tobacco pack-years (p-y) on overall (OS) and progression-free survival (PFS) for patients with oropharynx cancer (OPC) in Radiation Therapy Oncology Group (RTOG) protocol 9003. (2010) (13)
- Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma. (2022) (13)
- Prevalence and risk factors for oral DNA tumor viruses in HIV‐infected youth (2016) (13)
- Sinonasal adenoid cystic carcinoma: Treatment outcomes and association with human papillomavirus (2017) (13)
- Impact of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the U.S. (2017) (12)
- Development and validation of an individualized risk prediction model for oropharynx cancer in the US population (2019) (12)
- Incidence trends for human papillomavirus-related (HPV-R) and unrelated (HPV-U) head and neck squamous cell carcinomas (HNSCC) in the United States (US) (2007) (12)
- Human Papillomavirus and Oropharyngeal Cancer Stage. (2016) (11)
- Comprehensive control of human papillomavirus infections and related diseases. (2013) (11)
- Association of serum cytokines with oral HPV clearance. (2016) (11)
- Prognostic significance of human papillomavirus (HPV) tumor status for patients with head and neck squamous cell carcinoma (HNSCC) in a prospective, multi-center phase II clinical trial (2007) (11)
- Diverse tumorigenic consequences of human papillomavirus integration in primary oropharyngeal cancers (2021) (10)
- Safety Evaluation of Nivolumab Concomitant With Platinum-Based Chemoradiation therapy for Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504 (2018) (10)
- Human papillomavirus insertions identify the PIM family of serine/threonine kinases as targetable driver genes in head and neck squamous cell carcinoma. (2020) (10)
- E3311 trial of transoral surgery for oropharynx cancer: Implementation of a novel surgeon credentialing and quality assurance process. (2016) (10)
- Infection with Human Papilloma Virus (HPV) and risk of subsites within the oral cancer. (2021) (10)
- Prevalence of and Risk Factors for Oral Human Papillomavirus Infection among HIV-Positive and HIV-Negative People Who Inject Drugs (2015) (10)
- Characterization of potential predictive biomarkers of response to nivolumab in CheckMate 141 in patients with squamous cell carcinoma of the head and neck (SCCHN). (2017) (9)
- Head and Neck Cancer Risk Prediction Models for the US Population from the INHANCE Consortium. (2019) (9)
- Double-blind, two-arm, phase 2 study of nivolumab (nivo) in combination with ipilimumab (ipi) versus nivo and ipi-placebo (PBO) as first-line (1L) therapy in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)—CheckMate 714 (2016) (9)
- Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups (2018) (9)
- Human Papillomavirus and Head and Neck Cancer (2010) (8)
- Nivolumab (nivo) vs investigator’s choice (IC) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Analysis of CheckMate 141 by age. (2018) (8)
- Risk Prediction Models for Head and Neck Cancer in the US Population From the INHANCE Consortium (2019) (8)
- Symptom reduction from IMRT dose deintensification: Results from ECOG 1308 using the Vanderbilt Head and Neck Symptom Survey version 2 (VHNSS V2). (2015) (8)
- Human papillomavirus DNA detection, p16INK4a, and oral cavity cancer in a U.S. population. (2019) (8)
- Oral HPV infection in HPV-positive oropharyngeal cancer cases and their spouses. (2013) (8)
- Elective versus Therapeutic Neck Dissection in Oral Cancer. (2015) (8)
- Human Papillomavirus (HPV) 16 E6 seropositivity is elevated in subjects with oral HPV16 infection. (2016) (7)
- The Alpha, Beta, Gammas of Oral Human Papillomavirus Infection and Head and Neck Cancer Risk. (2016) (6)
- GEN-009, a neoantigen vaccine containing ATLAS selected neoantigens, to generate broad sustained immunity against immunogenic tumor mutations and avoid inhibitory peptides. (2020) (6)
- Head and Neck Squamous Cell Cancers in the Nonsmoker-Nondrinker (2005) (6)
- Impact of HPV vaccination on oral HPV infections among young adults in the U . S (2018) (6)
- Adapting Head and Neck Cancer Management in the Time of COVID-19 (2020) (6)
- Human Papillomavirus (HPV) and Overall Survival (OS) After Progression of Oropharyngeal Squamous Cell Carcinoma (OPSCC) (2014) (6)
- Independent association of marijuana use and poor oral hygiene with HPV–negative but not HPV–positive head and neck squamous cell carcinomas (2021) (5)
- Proton Therapy for Head and Neck Cancer: A 12-Year, Single-Institution Experience (2021) (5)
- Abstract CT157: Treatment beyond progression with nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck in the phase 3 Checkmate 141 study (2017) (5)
- Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651 (2022) (5)
- NRG-RTOG 1016: Phase III Trial Comparing Radiation/Cetuximab to Radiation/Cisplatin in HPV-related Cancer of the Oropharynx (2018) (5)
- Drug concentration-dependent DNA lesions are induced by the lipid-soluble antifolate, piritrexim (BW301U). (1986) (4)
- Risk factors for head and neck cancer in more and less developed countries: Analysis from the INHANCE Consortium. (2022) (4)
- Multi-Institutional Randomized Double-Blind Phase II Trial of Everolimus vs. Placebo as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN) (2020) (4)
- Long term results from a phase 1 trial of GEN-009, a personalized neoantigen vaccine, combined with PD-1 inhibition in advanced solid tumors. (2021) (4)
- Feasibility and acceptance of oral human papillomavirus detection in the dental office: Results from The National Dental Practice-Based Research Network. (2019) (4)
- Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141 (2022) (4)
- Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study. (2022) (4)
- The association of medication use with clearance or persistence of oral HPV infection (2016) (4)
- Predictive value of human papillomavirus (HPV) 16 in situ hybridization (ISH) and p16 immunohistochemistry (IHC) for HPV oncogene expression in paraffin-embedded oropharynx squamous cell carcinoma (OPSCC). (2011) (3)
- The Biological Basis for Enhanced Effects of Proton Radiation Therapy Relative to Photon Radiation Therapy for Head and Neck Squamous Cell Carcinoma (2021) (3)
- First-in-human phase I study of the bifunctional EGFR/TGFβ fusion protein BCA101 in patients with EGFR-driven advanced solid cancers. (2021) (3)
- Pathology Characterization and Detection of Human Papillomavirus Type 16 in Rectal Squamous Cell Carcinomas. (2019) (3)
- Abstract CT116: Nivolumab (Nivo) vs investigator's choice (IC) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): 2-yr outcomes in the overall population and PD-L1 subgroups of CheckMate 141 (2018) (3)
- Gender differences in risk factors and natural history of oral human papillomavirus ( HPV ) infection (2016) (3)
- 809 Phase 2 trial of neoadjuvant and adjuvant PD-1 checkpoint blockade in local-regionally advanced, resectable HNSCC indicates pathological response is associated with high disease-free survival (2020) (3)
- Intratumoral Heterogeneity and Clonal Evolution Induced by HPV Integration (2022) (3)
- 1055PNivolumab vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): treatment effect on clinical outcomes by best overall response in checkmate 141 (2017) (3)
- Proton Beam Therapy for Head and Neck Carcinoma of Unknown Primary: Toxicity and Quality of Life (2021) (3)
- The influence of institutional head and neck cancer (HNC) clinical trial accrual on overall survival (OS): An analysis of RTOG 0129. (2012) (3)
- A phase I trial of GEN-009, a neoantigen vaccine using ATLAS™, an autologous immune assay, to identify immunogenic and inhibitory tumour mutations (2019) (2)
- Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection. (2022) (2)
- 18 FDG PET/CT prediction of treatment outcomes in patients with p16-positive, non-smoking associated, locoregionally advanced oropharyngeal cancer (LA-OPC) receiving deintensified therapy: Results from NRG-HN002. (2020) (2)
- The AIM-HN Study: A pivotal study evaluating the efficacy of tipifarnib in patients with recurrent or metastatic head and neck squamous cell carcinoma with HRAS mutations. (2021) (2)
- Safety evaluation of nivolumab (Nivo) concomitant with platinum-based chemoradiotherapy (CRT) for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG Foundation 3504 (2018) (2)
- Mucosal Melanoma of the Head and Neck Clinical Practice Guidelines in Oncology (2012) (2)
- Predicting overall survival (OS) and progression-free (PFS) for oropharynx cancers (OPC) in NRG Oncology RTOG0129/0522 with nomograms. (2016) (2)
- Prognostic implication of persistent HPV16 DNA detection in oral rinses for HPV-positive oropharyngeal carcinoma. (2015) (2)
- Human immunodeficiency virus and lung cancer: differences in presentation and clinical course. (2005) (2)
- Toxicity and Pharyngeal Dysphagia Outcomes from Intensity Modulated Proton Therapy for Oropharyngeal Squamous Cell Cancer (2019) (2)
- Oropharyngeal carcinoma: A unique human papillomavirus-associated tumor of the head and neck (2011) (2)
- A phase I (Ph1) study of dasatinib (D) with cetuximab (Cet) /radiation (IMRT) +/- cisplatin (P) in stage II, III/IV head and neck squamous cell carcinoma (HNSCC). (2015) (2)
- Validation of NRG Oncology/RTOG 0129 Risk Groups for p16-Positive and p16-Negative Oropharyngeal Squamous Cell Cancer (OPSCC) (2016) (1)
- Neoadjuvant Pembrolizumab is Active in Surgically Resected Head and Neck Cancer (2018) (1)
- Molecular Pathways Human Papillomavirus in Head and Neck Cancer : Its Role in Pathogenesis and Clinical Implications (2009) (1)
- A phase I/II clinical trial of sorafenib in combination with cisplatin and docetaxel in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN). (2014) (1)
- Feasibility and acceptance of oral HPV detection in the dental office: results from the National Dental PBRN (2019) (1)
- Treatment De-Intensification for Patients With HPV-Positive Head and Neck Cancers (2022) (1)
- Organ Preservation in Head and Neck Cancer (2003) (1)
- Ultrasound in the Search for the Primary Site of Unknown Primary Head-and-Neck Squamous Cell Cancers (2014) (1)
- 975TiP Phase Ib trial of ABBV-368 + tilsotolimod in combination with nab-paclitaxel and/or budigalimab (ABBV-181) in patients with recurrent/metastatic head and neck squamous cell carcinoma (2020) (1)
- Incidence and clearance of anal human papillomavirus infection in 16 164 individuals, according to HIV status, gender, and male sexuality: an international pooled analysis of 34 longitudinal studies. (2022) (1)
- A Randomized Multi-Institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck. (2022) (1)
- Safety of nivolumab added to chemoradiotherapy platforms for intermediate and high-risk local-regionally advanced head and neck squamous cell carcinoma: RTOG Foundation 3504. (2022) (1)
- In Regard to Bossi et al. (2018) (1)
- Chapter 8. HPV vaccines and potential prevention of HPV-positive head and neck cancer (2014) (1)
- Title : Associations between oral HPV 16 infection and cytopathology : evaluation of an oropharyngeal “ Pap-test equivalent ” in high-risk populations (2011) (1)
- Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial. (2023) (1)
- head and neck cancerPatient-reported outcomes (PROs) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) treated with nivolumab (nivo) or investigator’s choice (IC): CheckMate 141 (2016) (1)
- Long‐term survival of a patient with leptomeningeal involvement by nasopharyngeal carcinoma after treatment with high‐dose intravenous methotrexate (2012) (1)
- 893P Clinico-genetic profiling of HRAS mutant head and neck squamous cell carcinoma (HNSCC) (2021) (1)
- Risk stratification after recurrence of human papillomavirus (HPV)‐related and non‐HPV‐related oropharyngeal cancer: Secondary analysis of NRG Oncology RTOG 0129 and 0522 (2021) (1)
- Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck (2021) (1)
- 383 First-in-man clinical trial of intratumoral injection of clostridium Novyi-NT spores in combination with pembrolizumab in patients with treatment-refractory advanced solid tumors (2020) (1)
- TIGIT as a therapeutic target of HPV-positive head and neck squamous cell carcinomas (2021) (1)
- Upper age limits for US male human papillomavirus vaccination for oropharyngeal cancer prevention: a microsimulation-based modeling study (2023) (1)
- 374 Discovery of a public HPV16-E6 directed T cell response that is associated with overall and progression free survival (2022) (0)
- Checkpoint inhibitors assessment in oropharynx carcinoma (CIAO). (2018) (0)
- University of Dundee Joint effects of intensity and duration of cigarette smoking on the risk of head and neck cancer (2019) (0)
- HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma (2023) (0)
- May 2 , 2019 Association of Oral Human Papillomavirus DNA Persistence With Cancer Progression After Primary Treatment for Oral Cavity and Oropharyngeal Squamous Cell Carcinoma (2019) (0)
- 08:50: Predictive Value of Measures of HPV Exposure and Infection (2007) (0)
- 390 Emerging safety and activity data from GEN-009–101: A phase 1/2a trial of GEN-009, a neoantigen vaccine in combination with PD-1 check-point inhibitors (CPI) in advanced solid tumors (2020) (0)
- 754 TIGIT-PVR is a key immune checkpoint and therapeutic target in HPV-positive head and neck squamous cell carcinomas (2021) (0)
- Abstract 132: Comprehensive genomic analysis of human papillomavirus-associated oral cancers (2016) (0)
- Abstract CT253: A Phase 1/2 trial to evaluate the safety and antitumor activity of tipifarnib and alpelisib for patients with HRAS-overexpressing and/or PIK3CA-mutated/amplified recurrent/metastatic head and neck squamous cell carcinoma (The KURRENT trial) (2022) (0)
- 18F-FDG PET/CT Prediction of Treatment Outcomes in Human Papillomavirus–Positive, Locally Advanced Oropharyngeal Cancer Patients Receiving Deintensified Therapy: Results from NRG-HN002 (2022) (0)
- Miniseminar: A Cancer Epidemic: Tonsils, Virus, Sex, and the Unknown (2007) (0)
- There is increasing molecular and epidemiologic evidence that human papillomavirus (HPV) is associated with a distinct subset of head and neck squamous cell carcinomas. The strength and consistency of HPV DNA presence in oropharyn- (2001) (0)
- Characterisation of Potential Predictive Biomarkers of Response to Nivolumab in Checkmate 141 in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) (2017) (0)
- The association of medication use with clearance or persistence of oral HPV infection (2016) (0)
- Comparison of Weekly and 3-weekly Cisplatin-based Chemoradiation Therapy Regimens for the Treatment of Patients With Stage III/IV Squamous Cell Head-and-Neck Cancer (2012) (0)
- EMERGING SAFETY AND ACTIVITY DATA FROM GEN- 009–101: A PHASE 1/2A TRIAL OF GEN-009, A NEOANTIGEN VACCINE IN COMBINATION WITH PD-1 CHECK-POINT INHIBITORS (CPI) IN ADVANCED SOLID TUMORS (2020) (0)
- Correction: A Phase I Trial of Erlotinib and Concurrent Chemoradiotherapy for Stage III and IV (M0) Squamous Cell Carcinoma of the Head and Neck (2012) (0)
- K4. Basic science (2009) (0)
- Immunotherapy of Head and Neck Cancer: summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 9-10, 2014, Bethesda, Maryland (2016) (0)
- Acknowledgment of Reviewers 2021. (2021) (0)
- Phase 1 study of SGN-PDL1V, a novel, investigational vedotin antibody–drug conjugate directed to PD-L1, in patients with advanced solid tumors (SGNPDL1V-001, trial in progress). (2022) (0)
- Prognostic Groups for p16-Positive Oropharyngeal Squamous Cell Cancer (p16-OPSCC) Treated With Chemoradiation Therapy (CRT) in NRG Oncology/RTOG 0129 and 0522 (2016) (0)
- Development of a Head and Neck Multidisciplinary Patient Education Binder (2016) (0)
- Abstract LB185: BBX and PLK1 feedback mechanisms regulate mitotic entry & exit (2021) (0)
- Abstract IA20: Radiotherapy plus cetuximab or cisplatin in human papilloma-virus positive oropharyngeal cancer (NRG 1016): A randomized multicenter noninferiority trial* (2020) (0)
- Human papillomavirus DNA detection, pl6 INK4a , and oral cavity cancer in a U.S. population (2019) (0)
- 31 COMPARATIVE PREDICTIVE VALUE OF E6 MRNA VERSUS HPV16 ISH FOR HUMAN OROPHARYNGEAL CARCINOMA (2009) (0)
- Recurrent or metastatic head and neck squamous cell carcinoma that is not responsive to platinum-based chemotherapy progresses very rapidly , and patients have a very poor prognosis , ” (2016) (0)
- Real-Time Quantitative PCR Demonstrates Low Prevalence of Human Papillomavirus Type 16 in Premalignant and Malignant Lesions of the Oral Cavity 1 (2002) (0)
- 485 Long term results from a phase 1 trial of GEN-009, a personalized neoantigen vaccine, combined with PD-1 inhibition in advanced solid tumors (2021) (0)
- Early prediction of anti-epidermal growth factor receptor (EGFR) therapy with 18[F]FDG-PET: A preclinical and clinical correlation (2007) (0)
- THE AUTHORS REPLY. (2017) (0)
- Abstract 643: Poor oral hygiene is associated with HPV-negative and not HPV-positive oral cancer (2019) (0)
- Racial differences in the relationship between tobacco, alcohol, and the risk of head and neck cancer: pooled analysis of US studies in the INHANCE Consortium (2018) (0)
- Prognostic Impact of Leukocyte Counts Before and During Radiation Therapy for Oropharyngeal Cancer (2018) (0)
- Bariatric Surgery for Morbid Obesity (2007) (0)
- A Phase 2/3, Randomized, Open-Label Study of Bempegaldesleukin Plus Pembrolizumab vs. Pembrolizumab Alone in First-Line Treatment of Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma with PD-L1-Expressing Tumors (PROPEL-36) (2022) (0)
- Alterations in oral bacterial communities are associated with risk factors for oral and oropharyngeal cancer (2017) (0)
- Abstract 4824: Little evidence of human papillomavirus in lung tumor tissue (2010) (0)
- Gastrostomy Tube Use in Head and Neck Cancer Survivors, Pre-Treatment Factors Supersede Treatment Intensification: A Second Analysis of RTOG 0129, RTOG 0522, and NRG/RTOG 1016 (2022) (0)
- Head and Neck CancersPractice Guidelines in Oncology (2011) (0)
- Herd Protection Against Oral HPV Infection-Reply. (2020) (0)
- Patient-Reported Outcomes after Intensity-Modulated Proton Therapy for Oropharynx Cancer (2021) (0)
- 568 Phase 2 trial of induction and concomitant CTLA4 (ipilimumab) and PD-1 (nivolumab) immune checkpoint blockade and intensity modulated radiation therapy (IMRT) in HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPSCC) (2022) (0)
- T .-C . Wu CARCINOMA DEVELOPMENT OF HPV VACCINES FOR HPV-ASSOCIATED HEAD AND NECK SQUAMOUS CELL (2003) (0)
- Abstract 4621: Risk stratification and biomarker discovery in HPV-positive oropharynx squamous cell carcinoma determined by HPV and human gene expression profile associations (2018) (0)
- PROGNOSTIC VALUE OF PRETREATMENT 18 F-FDG PET / CT VOLUME-BASED PARAMETERS IN PATIENTS WITH OROPHARYNGEAL SQUAMOUS CELL CARCINOMA WHOSE P 16 AND P 53 STATUS ARE KNOWN (2014) (0)
- Early prediction of antiepidermal growth factor receptor therapy with 18[F]FDG-PET: A preclinical and clinical correlation. (2007) (0)
- Abstract CT153: TiTAN: a phase 1 study of GEN-011, a neoantigen-targeted peripheral blood-derived T cell therapy with broad neoantigen targeting (2022) (0)
- Noninvasive genomic profiling of somatic mutations in oral cavity cancers. (2023) (0)
- Detection of Human Papillomavirus-16 in Fine-NeedleAspirates to DetermineTumor Origin in Patients withMetastatic Squamous Cell Carcinoma of the Head and Neck (2007) (0)
- 655MO Quality of life in patients with p16+ oropharyngeal cancer receiving accelerated radiotherapy (RT) with either cisplatin or cetuximab in NRG/RTOG 1016 (2022) (0)
- Molecular Epidemiology of Human Papillomavirus Infection (2008) (0)
- Representative oral microbiome data for the US population: the National Health and Nutrition Examination Survey. (2022) (0)
- 927TiP SKYSCRAPER-09: A phase II, randomised, double-blinded study of atezolizumab (Atezo) + tiragolumab (Tira) and atezo + placebo as first-line (1L) therapy for recurrent/metastatic (R/M) PD-L1+ squamous cell carcinoma of the head and neck (SCCHN) (2021) (0)
- Utility of Post-Chemoradiation Therapy FDG-PET/CT Response and PET Surveillance for Prediction of Locoregional Control in HPV-Related Oropharyngeal Cancer (2014) (0)
- P-242 HIV and lung cancer patients: Why such poor survival? (2005) (0)
- 1028P Clinical results of a pilot trial of GEN-009, a neoantigen vaccine containing immunogenic tumour specific neoantigens, in combination with PD-1 inhibitors in advanced cancers (2020) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Maura L. Gillison?
Maura L. Gillison is affiliated with the following schools:
